Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia

被引：0
|
作者：
Keyuan Zhang
Xiang Zhang
Yang Xu
Shengli Xue
Huiying Qiu
Xiaowen Tang
Yue Han
Suning Chen
Aining Sun
Yanming Zhang
Depei Wu
Ying Wang
机构：
[1] The First Affiliated Hospital of Soochow University,National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology
[2] Soochow University,Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology
[3] Key Laboratory of Thrombosis and Hemostasis of Ministry of Health,Department of Hematology
[4] The Affiliated Huai’an Hospital of Xuzhou Medical University and The Second People’s Hospital of Huai’an,State Key Laboratory of Radiation Medicine and Protection
[5] Soochow University,undefined
来源：
Blood Cancer Journal | / 13卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia
    Zhang, Keyuan
    Zhang, Xiang
    Xu, Yang
    Xue, Shengli
    Qiu, Huiying
    Tang, Xiaowen
    Han, Yue
    Chen, Suning
    Sun, Aining
    Zhang, Yanming
    Wu, Depei
    Wang, Ying
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [2] Efficacy of hypomethylating agents and Venetoclax in unfit patients with acute myeloid leukemia
    Rieger, M.
    Manz, M. G.
    Muller, R.
    Theocharides, A. P. A.
    Schwotzer, R.
    SWISS MEDICAL WEEKLY, 2020, : 17S - 17S
  • [3] Comparing the efficacy and safety of venetoclax combined with hypomethylating agents versus intensive chemotherapy as induction therapy in newly diagnosed core binding factor acute myeloid leukemia patients
    Shen, Jingyi
    Shan, Meng
    Chu, Mengqian
    Cai, Yiming
    Rui, Jingwen
    Chen, Suning
    Wu, Depei
    Xu, Yang
    BLOOD CANCER JOURNAL, 2025, 15 (01):
  • [4] How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia
    Brian A. Jonas
    Daniel A. Pollyea
    Leukemia, 2019, 33 : 2795 - 2804
  • [5] How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia
    Jonas, Brian A.
    Pollyea, Daniel A.
    LEUKEMIA, 2019, 33 (12) : 2795 - 2804
  • [6] Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients
    LeBlanc, Francis R.
    Breese, Erin H.
    Burns, Karen C.
    Chang, Ellen K.
    Jones, LaQuita M.
    Lee, Lynn
    Mizukawa, Benjamin
    Norris, Robin E.
    O'Brien, Maureen M.
    Phillips, Christine L.
    Perentesis, John P.
    Rubinstein, Jeremy
    Pommert, Lauren
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (03) : 1055 - 1066
  • [7] Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukaemia
    Liang, Peiqi
    Xie, Yan
    Liu, Ziyi
    Wang, Dong
    Li, Qian
    Lu, Yin
    Xue, Shengli
    Wang, Ying
    Chen, Suning
    Wu, Deipei
    Fu, Jianhong
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (04) : 1219 - 1226
  • [8] Hypomethylating Agents and Venetoclax in Acute Myeloid Leukemia
    DiNardo, Courtney D.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 82 - 83
  • [9] Impact of AML1/ETO Fusion on the Efficacy of Venetoclax Plus Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia
    Dian Jin
    Haoguang Chen
    Jingsong He
    Yi Li
    Gaofeng Zheng
    Yang Yang
    Yi Zhao
    Jing Le
    Wenxiu Shu
    Donghua He
    Zhen Cai
    Targeted Oncology, 2024, 19 : 237 - 249
  • [10] Impact of AML1/ETO Fusion on the Efficacy of Venetoclax Plus Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia
    Jin, Dian
    Chen, Haoguang
    He, Jingsong
    Li, Yi
    Zheng, Gaofeng
    Yang, Yang
    Zhao, Yi
    Le, Jing
    Shu, Wenxiu
    He, Donghua
    Cai, Zhen
    TARGETED ONCOLOGY, 2024, 19 (02) : 237 - 249
12345